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Background. South Africa implemented universal test and treat (UTT) in September 2016 in an effort to encourage earlier ini-
tiation of antiretroviral therapy (ART).
Methods. We therefore conducted an interrupted time series (ITS) analysis to assess the impact of UTT on mean CD4 count at 
ART initiation among adults aged ≥16 years attending 17 public sector primary care clinics in rural South Africa, between July 2014 
and March 2019.
Results. Among 20 599 individuals (69% women), CD4 counts were available for 74%. Mean CD4 at ART initiation in-
creased from 317.1 cells/μL (95% confidence interval [CI], 308.6 to 325.6) 1 to 8 months prior to UTT to 421.0 cells/μL (95% CI, 
413.0 to 429.0) 1 to 12 months after UTT, including an immediate increase of 124.2 cells/μL (95% CI, 102.2 to 146.1). However, 
mean CD4 count subsequently fell to 389.5 cells/μL (95% CI, 381.8 to 397.1) 13 to 30 months after UTT but remained above 
pre-UTT levels. Men initiated ART at lower CD4 counts than women (–118.2 cells/μL, 95% CI, –125.5 to –111.0) throughout 
the study.
Conclusions. Although UTT led to an immediate increase in CD4 count at ART initiation in this rural community, the long-
term effects were modest. More efforts are needed to increase initiation of ART early in those living with human immunodeficiency 
virus, particularly men.
Keywords.  HIV/AIDS; universal test and treat (UTT); CD4; antiretroviral therapy initiation.
Universal test and treat (UTT) aims to rapidly reduce AIDS-related 
deaths and incident human immunodeficiency virus (HIV) infec-
tions [1]. CD4+ T-cell counts are no longer required to determine 
antiretroviral therapy (ART) eligibility among people living with 
HIV [2, 3]. However, there are strong clinical indications to con-
tinue baseline CD4 testing, even with rapid ART initiation (ART 
initiation within 7 days of HIV diagnosis) [4], including that the 
CD4 count provides critical information on immune status and risk 
of opportunistic infections, enabling timely clinical interventions 
[2, 3] and disease care packages via a public health approach [4] as 
clinical stage does not accurately reflect actual immune status [5]; 
many individuals in low- and middle-income countries (LMIC) 
still present late to care [6, 7]; many individuals who reengage with 
care after treatment interruption have advanced HIV [8]; and risk 
of mortality is highest during the first few months of ART among 
those with lower CD4 counts at initiation [9, 10].
To initiate ART early in HIV infection, people living with HIV 
must first know their HIV status, link to care, and initiate ART. 
One summary measure of the timing of ART initiation in relation 
to HIV seroconversion is CD4 count at ART initiation. Unlike pre-
vious requirements for regular CD4 measurements until ART eli-
gible, under UTT we expect most individuals to have a single CD4 
measurement, their baseline CD4 measurement, which serves the 
dual function of CD4 count at diagnosis and CD4 at ART initia-
tion. Two previous studies in sub-Saharan Africa showed mixed 
results on the impact of CD4 eligibility expansions (to <350 cells/
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while median CD4 counts at ART initiation increased between 
2002 and 2015, they remained <350 cells/μL and increases were 
larger among women than among men in LMIC [12].
In January 2015, South Africa removed CD4 eligibility criteria for 
pregnant or breastfeeding women (Option B+) and expanded CD4 
eligibility criteria to ≤500 cells/μL for nonpregnant or breastfeeding 
adults [13]. South Africa implemented UTT in September 2016 
[14]. A critical question is whether this ambitious policy change re-
sulted in ART initiation earlier in HIV infection as anticipated.
We hypothesized that CD4 count at ART initiation would 
increase rapidly after UTT implementation as the backlog of 
people living with HIV who previously presented with CD4 
counts >500 cells/μL became eligible for ART. Following this 
short-term increase, we hypothesized that CD4 counts at ART 
initiation would remain high and continue increasing. We 
therefore examined short- and medium-term effects of UTT on 
mean CD4 count at ART initiation among men and women at-
tending public sector primary care clinics in rural South Africa.
METHODS
Study Setting and Design
This longitudinal study was conducted in the Hlabisa subdistrict 
of northern KwaZulu-Natal, at 17 nurse-led primary care clinics 
that are overseen by the local district hospital. CD4 and HIV viral 
load monitoring are routinely available. HIV prevalence is 30% 
[15]. Routine clinical data from the South African national ART 
program (TIER.Net) were sourced via the Africa Health Research 
Institute (AHRI) which has an agreement with the Department 
of Health (DoH) to access routine clinical data for research pur-
poses. National ART program data are captured by DoH clerical 
staff from patient medical records onto the TIER.Net database.
AHRI has operated a longitudinal population health and 
demographic surveillance system (HDSS) since 2003 in the area 
[16]. Since 2017, the AHRI HDSS has offered home-based HIV 
testing and linkage-to-care support and facilitates ART initia-
tion at DoH clinics [17]. Additional information on the study 
setting is provided in the Supplementary Material.
During all time periods analyzed in the present study, South 
African ART guidelines recommended baseline CD4 counts. 
Prior to 2015, CD4 testing was required at diagnosis for all 
adults and then every 6 months until ART eligible [18]. Baseline 
CD4 testing was also required during the Option B+ era [13]. 
Even during UTT (September 2016 onward) and the move to-
ward ART initiation on the same day as HIV diagnosis, the CD4 
count has remained a recommended baseline investigation [19].
Participants
We included all women and men living with HIV aged ≥16 years 
who commenced ART between 1 July 2014 and 31 March 2019 
at the 17 primary care clinics in Hlabisa subdistrict.
Outcomes and Exposures
The outcome of interest was CD4 count at ART initiation. We 
defined this as the closest CD4 count to the ART initiation date 
within a window of up to 6 months prior to the ART start date, 
or up to 3 months after the ART start date.
The main exposure of interest was calendar time by periods 
of CD4 count-based ART eligibility according to South African 
guidelines (Option B+ guideline in January 2015 and UTT guide-
line in September 2016) and by allowing 12 months for each new 
guideline to assimilate. We therefore divided calendar time as 
follows: prior to 1 January 2015 (“pre-Option B+”); 1 January 
2015 to 31 December 2015 (the 12 months following the Option 
B+ policy, titled “option B+ implementation” which occurred 
9–20 months prior to UTT); 1 January 2016 to 31 August 2016 
(“pre-UTT” which was 1–8 months prior to UTT); 1 September 
2016 to 31 August 2017 (“UTT implementation” which was 
1–12 months following UTT); and 1 September 2017 to 31 March 
2019 (“post UTT” which was 13–30 months following UTT).
Data Sources
We analyzed data from the South African national ART clinical 
database, TIER.Net, which registers and follows all individuals 
living with HIV from ART initiation [20]. TIER.Net includes 
laboratory results, ART regimen, ART switches, and visit dates. 
Pregnancy status was not available.
Statistical Analyses
We first summarized CD4 count categories at ART initiation by 
sex and time period. We also described time trends in the pro-
portion of individuals initiating ART without a baseline CD4 
count, due to concerns that health workers may not adhere to 
guideline recommendations. We then graphically represented 
time trends in mean CD4 count at ART initiation by sex using 
flexible semiparametric regression methods, namely, kernel-
weighted smoothed polynomial regression [21].
To measure the impact of UTT on CD4 count  at ART ini-
tiation, we performed segmented linear regression (interrupted 
time series [ITS] analyses) with a continuous time variable, bi-
nary exposure variables for each policy change, and time-by-
policy interaction terms [22]. The time-by-policy interaction 
term reflects the difference in slope between consecutive time 
periods (trend change) [22]. As each policy change may have 
taken time to assimilate, we allowed additional trend changes 
12  months after each official policy. We adjusted for missing 
CD4 counts by inverse probability weighting [23]. Specifically, 
we regressed availability of a within-window CD4 count on 
age category and clinic attended for ART initiation. We then 
used the inverse of the predicted probability of having a CD4 
count within the specified window in our main ITS regression 
model. We selected inverse probability weights over imputa-
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We also adjusted for sex in our main ITS regression model. 
Using regression post-estimation commands, we estimated 
average CD4 counts and actual trends (slopes) for each time 
period. We performed all statistical analysis in Stata 15.0 
(StataCorp, 2017, College Station, TX).
Ethical Approvals
The University of KwaZulu-Natal Biomedical Research Ethics 
Committee and the University of New South Wales Human 
Research Ethics Committee provided ethical approval.
RESULTS
A total of 20 599 individuals (69% women) aged ≥16 years com-
menced ART between July 2014 and March 2019. This included 
10 993 ART initiators after the UTT policy change in September 
2016. Median age at ART initiation was 30 years (interquartile range, 
25–38). The ART regimen at initiation was tenofovir disoproxil fu-
marate, emtricitabine, and efavirenz in 98% individuals.
A CD4 count was available for 16 454 (80%) ART initiators, 
of whom 15 265 had a CD4 count within the specified window 
(Figure 1). Most (97%) CD4 counts within the window were on 
or prior to the ART start date. Among the 15 265 individuals 
with a within-window CD4 count, 67% were women (Figure 1). 
Men initiating ART were older and had lower CD4 counts than 
women (Figure 2, Supplementary Table 1).
A large proportion of individuals initiated ART at CD4 counts 
≤200 cells/μL even after UTT. Compared with Option B+ imple-
mentation and pre-UTT periods, there were slight reductions 
in the proportion of individuals initiating ART at CD4 counts 
≤200 cells/μL after UTT (Figure 2, Supplementary Table 1). 
The total proportion of individuals initiating ART at CD4 
counts ≤200 cells/μL ranged from 27%–32% prior to the UTT 
policy change to 22%–26% after the UTT policy change.
The proportion of ART initiators without a baseline CD4 count 
increased over time. Among the 5334 individuals without a CD4 
count within the specified window, 4145 (78%) did not have a 
CD4 performed at all (Figure 1). The proportion of individuals 
who initiated ART without a CD4 count  appeared to increase with 
larger clinic size and was greater among women (Supplementary 
Table 2). There was an increasing time trend in the proportion of 
all individuals who initiated ART without a within-window CD4 
count, particularly after September 2016 (Figure 3). 
Time trends in CD4 count  at ART initiation are depicted 
in Figure 4. Women consistently initiated ART at higher CD4 
counts than men. There was a marked increase in CD4 count at 
ART initiation immediately after UTT, followed by a downward 
trend and stabilization thereafter.
Impact of Policy Changes on CD4 Count at ART Initiation
January 2015 to August 2016 (Option B+ implementation and pre-
UTT periods)
Immediately following the policy change in January 2015, 
mean CD4 count  at ART initiation increased by 52.7 cells/
μL (95% confidence interval [CI], 30.9 to 74.5). There was an 
upward absolute trend in CD4 count at ART initiation during 
pre-UTT of 3.1 cells/μL per month (95% CI, 0.5 to 5.7; Table 1).
The overall mean CD4 count was 324.9 cells/μL (95% CI, 319.3 
to 330.4) during Option B+ implementation (January 2015 to 
December 2015) and 317.1 cells/μL (95% CI, 308.6 to 325.6) pre-
UTT (January 2016 to August 2016). Mean CD4 counts among 
women and men are presented in Supplementary Table 1.
September 2016 to March 2019 (UTT implementation and post-UTT 
periods)
Immediately after the policy switch to UTT in September 2016, 
there was a marked increase in mean CD4 count at ART initia-
tion of 124.2 cells/μL (95% CI, 102.2 to 146.1). However, there 
was a downward absolute trend during the UTT implementa-
tion period (September 2016 to August 2017) of 5.6 cells/μL per 
month (95% CI, –7.5 to –3.8). The CD4 trend stabilized post-
UTT (Table 1).
Figure 1. Participant flow diagram for inclusion in regression models. 
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The overall mean CD4 count was 421.0 cells/μL (95% CI, 
413.0 to 429.0) during UTT implementation (September 2016 
to August 2017) and 389.5 cells/μL (95% CI, 381.8 to 397.1) 
post-UTT (September 2017 to March 2019). Mean CD4 counts 
among women and men are presented in Supplementary Table 
1. Men initiated ART at lower CD4 counts than women after 
adjusting for policy changes and trend changes (–118.2 cells/
μL, 95% CI, –125.5 to –111.0; Figure 4).
Figure 3. Time trends in proportion of individuals without a within-window CD4 count recorded. Dashed vertical lines depict policy change: January 2015, CD4 eligibility 
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DISCUSSION
We found that mean CD4 count at ART initiation signifi-
cantly increased immediately after the policy change to UTT. 
However, the longer-term effect of UTT on mean CD4 count 
at ART initiation was modest. Following the initial UTT policy 
rollout, mean CD4 count at ART initiation trended downward 
before stabilizing at approximately 70 cells/μL above pre-UTT 
baseline CD4 counts. Women consistently initiated ART at 
higher CD4 counts than men. The proportion of individuals 
Figure 4. CD4 count at ART initiation among women and men. Dashed vertical lines depict policy change: January 2015, CD4 eligibility cutoff ≤500 cells/μL for adults or 






/cid/advance-article/doi/10.1093/cid/ciab650/6328536 by guest on 17 N
ovem
ber 2021
CD4 at ART Initiation in South Africa • cid 2021:XX (XX XXXX) • 7
without baseline CD4 counts increased over time, particularly 
after the policy change to UTT. A large proportion of individ-
uals had advanced HIV at ART initiation despite the eligibility 
expansion.
The relative proportions of individuals starting ART at 
lower vs higher CD4 counts influence our observed mean CD4 
trends. If the majority of ART initiators had CD4 counts close 
to or above 500 cells/μL, we would expect the mean CD4 count 
after September 2016 to remain high and increase over time. 
Conversely, if lower CD4 count initiators remained the ma-
jority, clearing the backlog of previously ineligible individuals 
would result in a transient increase in mean CD4 count before 
approaching pre-UTT levels, as we observed. However, the 
more stable mean CD4  count after September 2017 of about 
70 cells/μL above pre-UTT levels attests to an overall medium-
term benefit of UTT on earlier ART initiation.
Several health service factors may explain these time trends 
and sex disparities in CD4 count  at ART initiation after the 
UTT policy change. First, there may have been a transient ex-
pansion of HIV testing shortly after the UTT policy change 
at facilities, as illustrated by a process evaluation of a trial 
conducted at 7 clinics in the area [24]. Second, staffing and 
other resource shortages may have limited timely implemen-
tation of the policy due to limited training or competing clin-
ical priorities [24, 25]. Moreover,  Health workers may have 
selectively conducted baseline CD4 tests among individuals 
they perceived to be at risk of advanced HIV, thereby diluting 
the impact of UTT on CD4 count  at ART initiation. Third, 
the historical policy focus on maternal and child health may 
have contributed to sex disparities in access to care [26, 27]. 
Inconvenient clinic operating hours or clinics being perceived 
as less “men friendly” [28] may have been additional factors. 
Men are more likely to start ART at later stages of HIV in-
fection than women [29, 30]. Although higher CD4 counts 
among women may be attributed to earlier HIV diagnosis and 
treatment during pregnancy, a study in South Africa found 
that only 7% of women who initiated ART were pregnant [30].
If people living with HIV do not access care at high CD4 
counts, they will not initiate ART at high CD4 counts. Although 
this study did not directly observe time of presentation, other 
studies have found that many individuals, particularly men, 
continue to present with low CD4 counts even in the UTT era 
[31, 32]. Linkage to care within 6 months of HIV diagnosis is 
poor in the AHRI catchment area, particularly among men 
[17]. Prevailing gender norms, including hegemonic mascu-
linity, may partly explain limited HIV care-seeking due to per-
ceptions of powerlessness [33].
Among the trials testing implementation of UTT prior to 
in-country policy change [34–38], median CD4 counts at 
ART initiation were 320–401 cells/μL and most participants 
were women [34, 39, 40]. Population-level reductions in HIV 
incidence were demonstrated in 2 UTT trials that included 
community-based HIV testing, facilitated linkage to care, and 
patient-centered clinical services [35, 37]. Other studies showed 
Table 1. Interrupted Time Series Regression: Mean CD4 Count at Antiretroviral Therapy Initiation by Time Period
Model  
parameter
Pre-Option B+ (July 
2014–December 2014)
Option B+ Implementation 
(January 2015–December 2015)
Pre-UTT (January  
2016–August 2016)






Coefficient (95% CI)  
P Value
Coefficient (95% CI)  
P Value
Coefficient (95% CI)  
P Value
Coefficient (95% CI)  
P Value





(–7.8 to 4.9)  
P = .647
N/A N/A N/A N/A
Level changeb N/A 52.7  
(30.9 to 74.5)  
P < .001
N/A 124.2  
(102.2 to 146.1)  
P < .001
N/A
Trend changec N/A –1.7  
(–8.3 to 4.8)  
P = .603
6.3  
(2.6 to 10.0)  
P = .001
–8.7  
(–11.9 to –5.5)  
P < .001
6.6  
(3.9 to 9.3)  
P < .001
Absolute trendd –1.5  
(–7.8 to 4.9)  
P = .647
–3.2  
(–4.7 to –1.7)  
P < .001
3.1  
(0.5 to 5.7)  
P = .021
–5.6  
(–7.5 to –3.8)  
P < .001
1.0  
(–0.3 to 2.2)  
P = .122
The regression model included inverse probability weights for availability of a within-window CD4 count, and a covariate for sex.
Abbreviations: CI, confidence interval; N/A, not applicable; UTT, universal test and treat.
a The underlying time trend refers to the “baseline” trend of CD4 count at antiretroviral therapy (ART) initiation in the analysis. Based on our models, this refers to the time trend in CD4 
count at ART initiation during the pre-option B+ period. Subsequent “absolute” time trends for each study period are calculated from this baseline, drawing on the modeled trend changes 
as described below.
bLevel changes were modeled at immediate policy change (option B+ policy change and UTT policy change) but not at 12 months after implementation of the policy.
cEach trend change is the change in trend relative to the (absolute) trend in the time period immediately preceding it. Therefore, the trend change for option B+ implementation relative to 
the pre-Option B+ trend is –1.7 cells/µL, and the trend change in pre-UTT relative to Option B+ implementation is +6.3 cells/µL.
dAbsolute trends were calculated using regression post-estimation commands (lincom in Stata). For example, the absolute trend for Option B+ implementation = pre-Option B+ time 
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that UTT was associated with ART initiation within 30 days of 
enrollment in care in some countries but not others [41]. These 
findings further highlight various health system considerations 
that are extraneous to the new policy including health service 
delivery challenges (including clinic congestion and nega-
tive health worker attitudes) [42], individual patient readiness 
for ART [42], limited uptake of HIV testing due to low per-
ceived risk or fear of stigma [43], and poor linkage to care [34]. 
Reassuringly, ART eligibility expansions do not appear to crowd 
out sicker patients despite increased demand for ART services 
in resource-poor settings [44, 45].
Our study adds to the emerging evidence for the impact of UTT 
on early ART initiation in sub-Saharan Africa. A key method-
ological strength of this quasiexperimental ITS analysis is the 
measurement of outcomes in a large group of individuals at-
tending services in a rural subdistrict: assuming population 
characteristics do not change over time, major sources of con-
founding are unlikely [22] and enable strong policy conclusions 
to be drawn. By measuring CD4 count at ART initiation, our 
outcome also indirectly measures coverage of HIV testing and 
linkage to care.
Our study has some limitations. First, we sourced CD4 re-
sults from the national clinical database, TIER.Net, which re-
lies on manual data entry from paper-based medical records; 
errors may have been introduced during data entry. It is also 
unknown whether the large number of missing CD4 counts re-
flects clinical process failure (from lack of sampling through to 
poor results turnaround) or gaps in TIER.Net record-keeping 
[46]. Second, the increasing proportion of missing CD4 values 
may have biased our results. However, we addressed this by as-
signing inverse probability weights in our regression model. 
Third, our findings may not be generalizable to other settings 
as factors that influence HIV testing, linkage to care, and ART 
initiation may differ. For instance, the Hawthorne phenom-
enon may have occurred at facilities in the subdistrict given 
the regular presence of AHRI research staff in several clinics 
[47]. Finally, our results may overestimate the impact of UTT 
on CD4 counts at initiation due to enhanced outreach activities 
in the AHRI catchment area.
Efforts to improve early ART initiation through enhanced 
HIV testing and linkage to care are critical, as are targeted inter-
ventions to boost male engagement with services. Interventions 
such as community-based multidisease screening [36], patient-
centered and personalized services [36], financial incentives 
[48], and community-based ART initiation and monitoring 
for men [49] have shown success. While the scalability and 
sustainability of such interventions are unknown, the need 
for a holistic approach—such as integrating HIV services with 
noncommunicable disease services, addressing the wider de-
terminants of health [50], reducing stigma, strengthening 
the health system including human and other resources, and 
improving health service quality—alongside more individual-
ized interventions remains.
Although CD4 counts no longer influence the decision to 
start ART, they are crucial to inform opportunistic infection 
risk stratification, targeted clinical management, and advanced 
disease care packages [3, 4]. This is particularly important given 
that one-third of people with HIV in LMIC still initiate ART 
late [7, 12], and there is an increased risk of early mortality 
among those without a pretherapy CD4 count [51].
CONCLUSIONS
Although UTT immediately increased earlier ART initiation, 
the longer-term effect was modest. An increasing proportion of 
ART initiators did not have a baseline CD4 count, and a large 
proportion were living with advanced HIV. Men started ART 
at lower CD4 counts than women. A multifaceted approach is 
required to improve service quality and address wider deter-
minants of health. Further research is needed to ascertain the 
long-term effects of UTT including virologic suppression and 
HIV incidence.
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